Game-changer for diabetes? Tandem’s Control-IQ+ automated insulin delivery system now available in the US
Tandem Diabetes Care launches Control-IQ+ automated insulin delivery for type 1 and type 2 diabetes, expanding access to advanced insulin automation in the U.S. Read More
Glenmark Pharmaceuticals expands cardiometabolic portfolio with new Empagliflozin drug launch
Glenmark Pharmaceuticals Ltd. has introduced Empagliflozin, a widely recognized SGLT2 inhibitor, in India under the brand name Glempa. Along with this, the company has launched ... Read More
Understanding Type 2 diabetes: Symptoms, causes, and treatment options
Type 2 diabetes is a chronic and increasingly prevalent health condition that affects millions worldwide. Characterised by elevated blood glucose levels, the disorder stems from ... Read More
Laparoscopic surgery: Pioneering a new frontier in Type 2 diabetes treatment
Type 2 diabetes, a chronic condition often managed through daily medication and insulin injections, may soon have a transformative treatment alternative: laparoscopic surgery. This minimally ... Read More
FDA approves first generic liraglutide injection for Type 2 diabetes treatment
In a significant milestone for diabetes care, the U.S. Food and Drug Administration (FDA) has approved the first generic equivalent of liraglutide injection, a glucagon-like ... Read More
Indoco Remedies secures FDA tentative approval for Canagliflozin Tablets
Indoco Remedies Ltd., a renowned player in the global pharmaceutical industry, has announced receiving tentative approval from the United States Food and Drug Administration (USFDA) ... Read More
Pfizer’s danuglipron shows promising results in Phase 2b obesity trial
Pfizer Inc. (NYSE: PFE) has announced encouraging topline data from its Phase 2b clinical trial (NCT04707313) investigating danuglipron, an oral Glucagon-like peptide-1 receptor agonist (GLP-1RA), ... Read More
Lilly bags Zepbound FDA approval for obesity treatment
The U.S. Food and Drug Administration has granted approval to Eli Lilly's Zepbound (tirzepatide) injection, making it the only obesity treatment that activates both GIP ... Read More
FDA approves ZITUVIMET by Zydus Lifesciences for Type 2 diabetes treatment
Zydus Lifesciences Limited has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for ZITUVIMET, a combination of Sitagliptin and ... Read More
Biocon and Juno Pharmaceuticals ink game-changing diabetes drug deal
Biocon Limited, the innovation-driven global biopharmaceutical frontrunner, has made headlines by sealing a significant partnership agreement with Juno Pharmaceuticals, Canada's esteemed specialty pharmaceutical giant. This ... Read More